{Reference Type}: Journal Article
{Title}: Expert consensus on the use of liraglutide in the treatment of diabetes in internal medicine.
{Author}: Calvo Gómez C;Gómez-Huelgas R;Lima Ruiz J;Masmiquel Comas L;Michán Doña A;Zapatero Gaviria A;
{Journal}: Int J Clin Pharmacol Ther
{Volume}: 54
{Issue}: 11
{Year}: Nov 2016
{Factor}: 0.976
{DOI}: 10.5414/CP202428
{Abstract}: <B>BACKGROUND: </B>Type 2 diabetes mellitus (DM2) is a disease of epidemic proportions. In the adult Spanish population, prevalence of DM2 is nearly 14%, which makes its monitoring and treatment imperative. Liraglutide has achieved relevance due to its efficacy and safety in DM treatment. The aim of this study is to gather expert opinion on diabetes to assess the current role of liraglutide in DM2.<BR><B>METHODS: </B>The survey was performed by 57 internal medicine specialists using the Delphi method. The questionnaire had 56 items regarding liraglutide in DM treatment.<BR><B>RESULTS: </B>Consensus was reached in 71.4% of items. Panelists stated agreement regarding liraglutide suitability in the treatment of patients with DM2, high cardiovascular risk, and with pathologies related to obesity, highlighting its role in weight loss, low risk of hypoglycemia, and improvement of vascular risks. Moreover, consensus was not reached regarding the suitability of liraglutide in patients with special situations, mainly due to minimal experience caused by the small number of patients.<BR><B>CONCLUSIONS: </B>Due to its safety and hypoglycemic efficacy, liraglutide is an excellent choice for DM treatment in combination with other drugs. Its effects on the reduction of weight and other cardiovascular risk factors, make it an optimal treatment, especially in overweight or obese patients.